PL2322546T3 - Acylowane związki GLP-1 - Google Patents

Acylowane związki GLP-1

Info

Publication number
PL2322546T3
PL2322546T3 PL10169546T PL10169546T PL2322546T3 PL 2322546 T3 PL2322546 T3 PL 2322546T3 PL 10169546 T PL10169546 T PL 10169546T PL 10169546 T PL10169546 T PL 10169546T PL 2322546 T3 PL2322546 T3 PL 2322546T3
Authority
PL
Poland
Prior art keywords
compounds
acylated glp
glp
acylated
therapeutic uses
Prior art date
Application number
PL10169546T
Other languages
English (en)
Polish (pl)
Inventor
Jesper Lau
Florencio Zaragoza Dörwald
Henrik Stephensen
Paw Bloch
Thomas Kruse Hansen
Kjeld Madsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36821525&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2322546(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of PL2322546T3 publication Critical patent/PL2322546T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
PL10169546T 2005-03-18 2006-03-20 Acylowane związki GLP-1 PL2322546T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05102171 2005-03-18
EP10169546.8A EP2322546B1 (en) 2005-03-18 2006-03-20 Acylated GLP-1 compounds
EP06725149A EP1863839B1 (en) 2005-03-18 2006-03-20 Acylated glp-1 compounds

Publications (1)

Publication Number Publication Date
PL2322546T3 true PL2322546T3 (pl) 2016-03-31

Family

ID=36821525

Family Applications (2)

Application Number Title Priority Date Filing Date
PL06725149T PL1863839T3 (pl) 2005-03-18 2006-03-20 Związki acylowanego GLP-1
PL10169546T PL2322546T3 (pl) 2005-03-18 2006-03-20 Acylowane związki GLP-1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL06725149T PL1863839T3 (pl) 2005-03-18 2006-03-20 Związki acylowanego GLP-1

Country Status (23)

Country Link
US (2) US8129343B2 (OSRAM)
EP (2) EP1863839B1 (OSRAM)
JP (3) JP5209463B2 (OSRAM)
KR (1) KR101205272B1 (OSRAM)
CN (3) CN104017062A (OSRAM)
AT (1) ATE476446T1 (OSRAM)
AU (1) AU2006224536B9 (OSRAM)
BR (2) BRPI0607762B8 (OSRAM)
CA (1) CA2601784C (OSRAM)
DE (1) DE602006015928D1 (OSRAM)
DK (2) DK2322546T3 (OSRAM)
ES (2) ES2350051T3 (OSRAM)
HU (2) HUE028194T2 (OSRAM)
IL (1) IL184051A (OSRAM)
MX (1) MX2007011220A (OSRAM)
NL (1) NL300936I2 (OSRAM)
NO (2) NO337946B1 (OSRAM)
PL (2) PL1863839T3 (OSRAM)
PT (2) PT1863839E (OSRAM)
RU (1) RU2434019C3 (OSRAM)
TW (2) TWI372629B (OSRAM)
WO (1) WO2006097537A2 (OSRAM)
ZA (1) ZA200707261B (OSRAM)

Families Citing this family (239)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
KR101241862B1 (ko) * 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
EP1799711B1 (en) 2004-10-07 2012-06-20 Novo Nordisk A/S Protracted exendin-4 compounds
US7893017B2 (en) 2004-10-07 2011-02-22 Novo Nordisk A/S Protracted GLP-1 compounds
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
WO2006097538A1 (en) * 2005-03-18 2006-09-21 Novo Nordisk A/S Extended glp-1 compounds
TWI372629B (en) * 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
CN100374462C (zh) * 2005-11-21 2008-03-12 大连帝恩生物工程有限公司 截短胰高血糖素样肽1(sGLP-1)、制法及其应用
US7704977B2 (en) 2006-04-07 2010-04-27 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US20090326193A1 (en) * 2006-06-23 2009-12-31 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
US7425542B2 (en) * 2006-06-23 2008-09-16 Aegis Therapeutics, Inc. Stabilizing alkylglycoside compositions and methods thereof
US8173594B2 (en) * 2006-06-23 2012-05-08 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US7998927B2 (en) * 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
US8084022B2 (en) * 2006-06-23 2011-12-27 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
EP2190872B1 (en) 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
EP2190460B1 (en) * 2007-09-05 2014-12-17 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
EP2190873B1 (en) * 2007-09-05 2015-07-22 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
CA2705821A1 (en) 2007-11-16 2009-05-22 Novo Nordisk A/S Pharmaceutical compositions containing insulin and an insulinotropic peptide
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
PT2910570T (pt) 2008-03-18 2017-01-24 Novo Nordisk As Análogos de insulina acilados, estabilizados contra proteases
EP2271347B1 (en) 2008-03-28 2016-05-11 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
JP5671451B2 (ja) 2008-05-07 2015-02-18 メリオン・リサーチ・Ｉｉｉ・リミテッド ＧｎＲＨ関連化合物の組成物および調製プロセス
MX2011000847A (es) * 2008-08-06 2011-02-25 Novo Nordisk Healthcare Ag Proteinas conjugadas con eficacia prolongada in vivo.
US8637647B2 (en) 2008-09-12 2014-01-28 Novo Nordisk A/S Method of acylating a peptide or protein
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
JP5816097B2 (ja) 2009-01-22 2015-11-18 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
JP5599822B2 (ja) 2009-01-23 2014-10-01 ノヴォ ノルディスク アー／エス アルブミンバインダーａ−ｂ−ｃ−ｄ−ｅ−を有するｆｇｆ２１誘導体及びそれらの使用
WO2010142665A1 (en) * 2009-06-11 2010-12-16 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
JP6054742B2 (ja) 2009-07-13 2016-12-27 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体
US8841249B2 (en) 2009-08-06 2014-09-23 Novo Nordisk A/S Growth hormones with prolonged in-vivo efficacy
JP2013514322A (ja) 2009-12-16 2013-04-25 ノヴォ ノルディスク アー／エス 修飾されたｎ末端を有するｇｌｐ−１受容体アゴニスト化合物
SI2525834T1 (sl) 2010-01-22 2019-10-30 Novo Nordisk Healthcare Ag Rastni hormoni s podaljšano in vivo učinkovitostjo
AU2011208620B2 (en) 2010-01-22 2015-04-16 Novo Nordisk Health Care Ag Stable growth hormone compounds
US20130012432A1 (en) 2010-02-26 2013-01-10 Novo Nordisk A/S Peptides for Treatment of Obesity
WO2011120033A1 (en) 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
AU2011231503C1 (en) * 2010-03-26 2016-03-03 Novo Nordisk A/S Novel glucagon analogues
CN102186881B (zh) * 2010-04-27 2015-04-08 贝达药业股份有限公司 胰高血糖素样肽-1衍生物及其应用
US8951959B2 (en) * 2010-04-27 2015-02-10 Betta Pharmaceuticals Co., Ltd. Glucagon-like peptide-1 analogues and uses thereof
WO2011143788A1 (en) * 2010-05-17 2011-11-24 Zhejiang Beta Pharma Inc. Novel glucagon like peptide analogs, composition, and method of use
WO2012016419A1 (zh) * 2010-08-06 2012-02-09 浙江贝达药业有限公司 Glp-1衍生物及其应用
JP6231386B2 (ja) 2010-11-09 2017-11-15 ノヴォ ノルディスク アー／エス リンカーを有する二重アシル化されたｇｌｐ−１誘導体
PL3326620T3 (pl) 2010-12-16 2020-08-24 Novo Nordisk A/S Kompozycje stałe zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino)kaprylowego
US8802114B2 (en) 2011-01-07 2014-08-12 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
WO2012098187A1 (en) 2011-01-19 2012-07-26 Novo Nordisk A/S Glp-1 compositions
WO2012098188A1 (en) 2011-01-19 2012-07-26 Novo Nordisk A/S Glp-1 particles and compositions
CN103596583B (zh) * 2011-03-28 2016-07-27 诺沃—诺迪斯克有限公司 新型胰高血糖素类似物
JP5871905B2 (ja) * 2011-03-30 2016-03-01 ベータ ファーマシューティカルズ カンパニー リミテッド グルカゴン様ペプチド−１類似体およびその使用
BR112013026195A2 (pt) * 2011-04-12 2016-11-29 Novo Nordisk As derivados de glp-1 duplamente acilados
ES2712945T3 (es) * 2011-04-12 2019-05-16 Novo Nordisk As Derivados de GLP-1 doblemente acilados
EP3415139B8 (en) 2011-06-14 2022-05-18 Neurelis, Inc. Administration of benzodiazepine
RU2014103185A (ru) 2011-07-18 2015-08-27 Артс Байолоджикс А/С Биологически активное соединение на основе лютеинизирующего гормона (lh) с пролонгированным действием
CN104039822A (zh) 2011-09-06 2014-09-10 诺沃—诺迪斯克有限公司 Glp-1衍生物
CA2849673A1 (en) 2011-09-23 2013-03-28 Novo Nordisk A/S Novel glucagon analogues
CN110041399B (zh) 2011-12-29 2023-12-12 诺沃—诺迪斯克有限公司 包含非成蛋白质性的氨基酸的二肽
SMT201700488T1 (it) 2012-02-15 2017-11-15 Novo Nordisk As Anticorpi che legano e bloccano il recettore d'innesco espresso sulle cellule mieloidi-1 (trem-1)
SI2814842T1 (sl) 2012-02-15 2018-10-30 Novo Nordisk A/S Protitelesa, ki vežejo peptidoglikal prepoznan protein 1
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
CN111494323B (zh) 2012-03-22 2023-03-28 诺和诺德股份有限公司 包含递送剂的组合物及其制备
HUE062740T2 (hu) 2012-03-22 2023-12-28 Novo Nordisk As GLP-1 peptidek készítményei és elõállításuk
PT2827885T (pt) * 2012-03-22 2018-11-05 Novo Nordisk As Composições de péptidos glp-1 e sua preparação
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
JP6228187B2 (ja) 2012-05-03 2017-11-08 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
JP6250034B2 (ja) 2012-05-08 2017-12-20 ノヴォ ノルディスク アー／エス 二重アシル化されたｇｌｐ−１誘導体
EP2846824B1 (en) 2012-05-08 2017-04-05 Novo Nordisk A/S Double-acylated glp-1 derivatives
EP2851429B1 (en) 2012-05-18 2019-07-24 Adda Biotech Inc. Protein and protein conjugate for diabetes treatment, and applications thereof
US9993430B2 (en) 2012-06-20 2018-06-12 Novo Nordisk A/S Tablet formulation comprising semaglutide and a delivery agent
DK2866825T3 (da) 2012-07-01 2020-06-08 Novo Nordisk As Anvendelse af langstidsvirkende glp-1-peptider
MX356957B (es) 2012-07-23 2018-06-20 Zealand Pharma As Analogos del glucagon.
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
WO2014060472A1 (en) 2012-10-17 2014-04-24 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
CN105120887A (zh) 2013-04-05 2015-12-02 诺和诺德保健股份有限公司 生长激素化合物制剂
PL2986313T3 (pl) 2013-04-18 2019-12-31 Novo Nordisk A/S Stabilni, dłużej działający współagoniści receptora glp-1/glukagonu do zastosowań medycznych
PT2991671T (pt) 2013-05-02 2018-11-05 Novo Nordisk As Dosagem oral de compostos de glp-1
MX2015016564A (es) * 2013-06-20 2016-04-15 Novo Nordisk As Derivados de peptido similar al glucaton tipo 1 (glp-1) y uso de los mismos.
KR20160029079A (ko) 2013-07-04 2016-03-14 노보 노르디스크 에이/에스 Glp-1 유사 펩티드의 유도체 및 그것의 사용
CN105451776B (zh) 2013-08-15 2020-04-17 诺和诺德股份有限公司 Glp-1衍生物及其用途
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
JP6822839B2 (ja) * 2013-09-13 2021-01-27 ザ・スクリップス・リサーチ・インスティテュート 修飾された治療剤、及びその組成物
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
CA2926314C (en) 2013-10-17 2023-08-29 Zealand Pharma A/S Acylated glucagon analogues
CN105829339B (zh) 2013-11-06 2021-03-12 西兰制药公司 胰高血糖素-glp-1-gip三重激动剂化合物
AU2014345569B2 (en) 2013-11-06 2020-08-13 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
AU2014359894B2 (en) 2013-12-06 2020-09-17 Baikang (Suzhou) Co., Ltd Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
CN106456589B (zh) 2013-12-18 2020-07-07 斯克利普斯研究所 修饰的治疗剂、订合的肽脂质缀合物及其组合物
KR20160114082A (ko) 2014-02-18 2016-10-04 노보 노르디스크 에이/에스 안정한 글루카곤 유사체 및 저혈당증의 치료를 위한 용도
EP3129041B1 (en) 2014-04-07 2019-06-12 Novo Nordisk A/S Double-acylated glp-1 compounds
TWI668010B (zh) 2014-05-07 2019-08-11 丹麥商諾佛 儂迪克股份有限公司 使用ｇｌｐ－１及抗ｉｌ－２１治療糖尿病
JP2017525656A (ja) 2014-06-04 2017-09-07 ノヴォ ノルディスク アー／エス 医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト
SI3172232T1 (sl) 2014-07-17 2024-05-31 Novo Nordisk A/S Na mesto usmerjena mutageneza protiteles TREM-1 za zmanjšanje viskoznosti
US10968266B2 (en) 2014-09-05 2021-04-06 University Of Copenhagen GIP peptide analogues
GR20140100479A (el) * 2014-09-23 2016-05-05 Novetide, Ltd., Συνθεση λιραγλουτιδης
ES2630106T3 (es) 2014-10-07 2017-08-18 Cyprumed Gmbh Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
EP3212218B1 (en) 2014-10-29 2021-06-30 Zealand Pharma A/S Gip agonist compounds and methods
CN106999602B (zh) 2014-11-27 2022-02-01 诺和诺德股份有限公司 Glp-1衍生物及其用途
US10392428B2 (en) 2014-12-17 2019-08-27 Novo Nordisk A/S GLP-1 derivatives and uses thereof
AR103246A1 (es) 2014-12-23 2017-04-26 Novo Nordiks As Derivados de fgf21 y sus usos
CN107205948B (zh) * 2015-01-29 2021-12-14 诺和诺德股份有限公司 包含glp-1激动剂和肠溶衣的片剂
US20180263915A1 (en) * 2015-01-29 2018-09-20 Novo Nordisk A/S Pharmaceutical Composition for Oral GLP-1 Administration Comprising a Tablet Core and Immediate Release Coating
CA2980978A1 (en) 2015-04-16 2016-10-20 Zealand Pharma A/S Acylated glucagon analogue
JP2018517745A (ja) * 2015-06-16 2018-07-05 サン、ファーマ、アドバンスト、リサーチ、カンパニー、リミテッドＳｕｎ Ｐｈａｒｍａ Ａｄｖａｎｃｅｄ Ｒｅｓｅａｒｃｈ Ｃｏｍｐａｎｙ Ｌｉｍｉｔｅｄ 長時間作用リラグルチド組成物
CN107921098A (zh) 2015-06-17 2018-04-17 加州生物医学研究所 修饰的治疗剂及其组合物
CN106554403B (zh) * 2015-09-25 2021-08-31 博瑞生物医药（苏州）股份有限公司 艾塞那肽修饰物及其用途
CN106554408A (zh) * 2015-09-30 2017-04-05 天津药物研究院有限公司 长效胰高血糖素样肽-1类似物二聚体及其应用
CN106554409B (zh) * 2015-09-30 2020-04-07 天津药物研究院有限公司 一种长效胰高血糖素样肽-1类似物及其应用
AU2016335287A1 (en) 2015-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs
CN106928343A (zh) * 2015-12-30 2017-07-07 深圳翰宇药业股份有限公司 索玛鲁肽的制备方法
US10946074B2 (en) 2016-03-03 2021-03-16 Novo Nordisk A/S GLP-1 derivatives and uses thereof
CN107266557B (zh) * 2016-04-06 2020-04-07 天津药物研究院有限公司 一种聚乙二醇修饰的胰高血糖素样肽-1类似物
KR102778218B1 (ko) * 2016-04-28 2025-03-10 노보 노르디스크 에이/에스 심혈관 병태에서의 세마글루타이드
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
WO2018078112A1 (en) 2016-10-27 2018-05-03 Aarhus Universitet Glp-1 agonist (eg liraglutide) for use in the treatment of multiple sclerosis
JP7076442B2 (ja) 2016-11-07 2022-05-27 ノヴォ ノルディスク アー／エス Ｐｅｇ化合物のｄｃｈｂｓ活性エステル及びその使用
PT3554534T (pt) 2016-12-16 2021-11-05 Novo Nordisk As Composições farmacêuticas contendo insulina
CN107033234B (zh) * 2017-01-03 2018-06-26 北京凯因科技股份有限公司 酰化的glp-1衍生物
CN110545838A (zh) * 2017-03-08 2019-12-06 因塔西亚制药公司 用于从药物递送装置施用致恶心化合物的设备和方法
KR102743887B1 (ko) 2017-05-31 2024-12-19 유니버시티 오브 코펜하겐 장기-작용성 gip 펩타이드 유사체
TWI797133B (zh) 2017-06-09 2023-04-01 丹麥商諾佛 儂迪克股份有限公司 用於經口投予的固體組成物
CN109248323B (zh) * 2017-07-14 2023-09-08 杭州先为达生物科技有限公司 酰化的glp-1衍生物
WO2019016306A1 (en) * 2017-07-19 2019-01-24 Novo Nordisk A/S BIFUNCTIONAL COMPOUNDS
JP6633777B2 (ja) 2017-08-24 2020-01-22 ノヴォ ノルディスク アー／エス Ｇｌｐ−１組成物及びその使用
CN111163795A (zh) 2017-09-10 2020-05-15 诺沃挪第克公司 用于治疗肥胖症的mic-1和glp-1
US11357861B2 (en) 2017-09-29 2022-06-14 Hanmi Pharm. Co., Ltd Protein complex comprising non-peptidyl polymer-coupled fatty acid derivative compound as linker and preparation method therefor
MA50358A (fr) 2017-10-12 2020-08-19 Novo Nordisk As Sémaglutide en thérapie médicale
CN107881187A (zh) * 2017-11-20 2018-04-06 珠海联邦制药股份有限公司 将大肠杆菌表达的融合蛋白转化为利拉鲁肽的制备方法及应用
EP3728304B1 (en) * 2017-12-21 2025-02-12 Bachem Holding AG Solid phase synthesis of acylated peptides
SG11202006595RA (en) 2018-02-02 2020-08-28 Novo Nordisk As Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
WO2019157099A1 (en) 2018-02-06 2019-08-15 Aegis Therapeutics, Llc Intranasal epinephrine formulations and methods for the treatment of disease
CN110294800B (zh) * 2018-03-22 2022-03-04 齐鲁制药有限公司 一种索玛鲁肽的制备方法
EA202092302A1 (ru) 2018-04-02 2021-02-02 Бристол-Майерс Сквибб Компани Антитела к trem-1 и их применения
DK3774862T3 (da) * 2018-04-05 2022-09-05 Sun Pharmaceutical Ind Ltd Nye GLP-1-analoger
EP3773475A1 (en) 2018-04-06 2021-02-17 Cyprumed GmbH Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
WO2019200594A1 (zh) * 2018-04-19 2019-10-24 杭州先为达生物科技有限公司 酰化的glp-1衍生物
CN115814064A (zh) * 2018-04-19 2023-03-21 杭州先为达生物科技有限公司 Glp-1衍生物及其治疗用途
EP3788063B1 (en) 2018-05-04 2023-08-09 Novo Nordisk A/S Gip derivatives and uses thereof
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
MY206306A (en) 2018-10-26 2024-12-07 Novo Nordisk As Stable semaglutide compositions and uses thereof
CN109180801B (zh) * 2018-11-01 2021-08-13 汉肽生物医药集团有限公司 一种合成索玛鲁肽的方法
EP3891173A1 (en) 2018-12-03 2021-10-13 Antag Therapeutics ApS Modified gip peptide analogues
WO2020127476A1 (en) 2018-12-19 2020-06-25 Krka, D.D., Novo Mesto Pharmaceutical composition comprising glp-1 analogue
WO2020127950A1 (en) 2018-12-21 2020-06-25 Novo Nordisk A/S Process of spray drying of glp-1 peptide
WO2020152304A1 (en) 2019-01-24 2020-07-30 Novo Nordisk A/S Roller compactor and method of dry granulation using a roller compactor
CN119455003A (zh) 2019-02-12 2025-02-18 Ambrx公司 包含抗体-tlr激动剂缀合物的组合物、方法和用途
MA55008A (fr) 2019-02-20 2021-12-29 Novo Nordisk As Aminoacyl-arnt synthétases et leurs utilisations
WO2020190757A1 (en) 2019-03-15 2020-09-24 Novetide Ltd. Improved processes for the preparation of semaglutide
WO2020187712A1 (en) 2019-03-15 2020-09-24 Novo Nordisk A/S Process for spray drying a glp-1 peptide
CN111748019A (zh) * 2019-03-29 2020-10-09 深圳翰宇药业股份有限公司 一种多肽衍生化合物的合成方法
WO2020201280A1 (en) 2019-04-01 2020-10-08 Novo Nordisk A/S Antibodies directed against liraglutide and use thereof
MX2021012277A (es) * 2019-04-11 2021-11-12 Jiangsu Hansoh Pharmaceutical Group Co Ltd Agonista multireceptor y uso medico del mismo.
CN111909256A (zh) * 2019-05-10 2020-11-10 宁波鲲鹏生物科技有限公司 多肽衍生物及其制备方法
JP2022533674A (ja) * 2019-05-21 2022-07-25 メディミューン リミテッド シクロデキストリンをベースとするｓｇｌｔ２阻害剤及びインクレチンペプチドの注射用共製剤
WO2021043803A1 (en) 2019-09-02 2021-03-11 Novo Nordisk A/S Process for producing a tablet comprising glp-1 peptides
CN114616242A (zh) * 2019-09-16 2022-06-10 生物马林药物股份有限公司 Cnp变体和其共轭物
CN110590934B (zh) * 2019-09-25 2020-12-08 北京乐普医药科技有限公司 一种glp-1化合物
KR20220110731A (ko) 2019-11-06 2022-08-09 노보 노르디스크 에이/에스 치매에서의 glp-1 수용체 작용제
EP4054536A1 (en) 2019-11-07 2022-09-14 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
EP3819308A1 (en) 2019-11-07 2021-05-12 Fresenius Kabi iPSUM S.r.l. Process for the manufacture of derivatized amino acids
WO2021105393A1 (en) 2019-11-29 2021-06-03 Novo Nordisk A/S Processes for obtaining stable glp-1 compositions
WO2021123228A1 (en) 2019-12-18 2021-06-24 Krka, D.D., Novo Mesto Pharmaceutical composition comprising glp-1 analogue
KR20220119731A (ko) * 2019-12-30 2022-08-30 간 앤 리 파마슈티칼스 컴퍼니, 리미티드 장기 지속형 glp-1 화합물
WO2021136223A1 (en) 2019-12-31 2021-07-08 Beijing Ql Biopharmaceutical Co., Ltd. Fusion proteins of glp-1 and gdf15 and conjugates thereof
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
CN119874775A (zh) 2020-02-07 2025-04-25 加舒布鲁姆生物公司 杂环glp-1激动剂
CN115484935A (zh) 2020-02-14 2022-12-16 G2G生物公司 包括含有glp-1类似物或其药学上可接受的盐的缓释微球的药物组合物
AU2021208601B2 (en) 2020-02-18 2025-06-05 Novo Nordisk A/S Glp-1 compositions and uses thereof
CN111253475B (zh) * 2020-02-18 2021-03-09 江苏诺泰澳赛诺生物制药股份有限公司 Glp-1激动多肽化合物及其盐与合成方法及用途
EP4132960A2 (en) 2020-04-10 2023-02-15 Fresenius Kabi Oncology Limited An improved process for the preparation of semaglutide side chain
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
US20230165939A1 (en) 2020-04-29 2023-06-01 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and histidine
AR122579A1 (es) * 2020-06-12 2022-09-21 Lilly Co Eli Proceso para preparar un agonista dual glp-1 / glucagón
EP4185606A1 (en) 2020-07-22 2023-05-31 Novo Nordisk A/S Glp-1 and gip receptor co-agonists
WO2022028572A1 (en) 2020-08-06 2022-02-10 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
AU2021327396A1 (en) 2020-08-20 2023-03-23 Ambrx, Inc. Antibody-TLR agonist conjugates, methods and uses thereof
CN116419750A (zh) 2020-09-07 2023-07-11 西普鲁梅有限公司 改进的glp-1受体激动剂的药物制剂
KR20230083294A (ko) * 2020-09-30 2023-06-09 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 폴리펩타이드 접합체 및 사용 방법
WO2022096636A1 (en) 2020-11-06 2022-05-12 Novo Nordisk A/S Glp-1 prodrugs and uses hereof
TWI850611B (zh) 2020-12-18 2024-08-01 丹麥商諾佛 儂迪克股份有限公司 Glp-1及澱粉素受體之共促效劑
CN115124602B (zh) 2021-03-25 2024-01-26 博瑞生物医药（苏州）股份有限公司 Gip和glp-1的双受体激动剂、药物组合物及用途
MX2023011480A (es) 2021-04-03 2023-12-06 Ambrx Inc Conjugados anticuerpo anti-her2-fármaco y usos de estos.
TW202304500A (zh) 2021-04-21 2023-02-01 瑞士商諾華公司 升糖素樣肽化合物
JP2024522196A (ja) 2021-06-09 2024-06-11 ザ スクリプス リサーチ インスティテュート 長時間作用型デュアルｇｉｐ／ｇｌｐ－１ペプチドコンジュゲートおよび使用方法
JP2024521398A (ja) 2021-06-10 2024-05-31 アンタグ セラピューティクス エーピーエス 肥満及び肥満関連障害の治療
EP4360623A4 (en) 2021-06-23 2025-06-04 Peptron, Inc. DELAYED-RELEASE FORMULATION CONTAINING SEMAGLUTIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
EP4360642A4 (en) 2021-06-25 2025-09-10 Gan & Lee Pharmaceuticals Co Ltd PHARMACEUTICAL COMPOSITION OF PCSK9 INHIBITOR AND GLP-1 RECEPTOR AGONIST
WO2022268213A1 (zh) * 2021-06-25 2022-12-29 甘李药业股份有限公司 含glp-1化合物的药物组合物
WO2023285334A1 (en) 2021-07-12 2023-01-19 Novo Nordisk A/S Novel fatty acid modified urocortin 2 derivatives and the uses thereof
WO2023284822A1 (en) 2021-07-14 2023-01-19 Beijing Ql Biopharmaceutical Co., Ltd. Fusion polypeptides for metabolic disorders
AU2022312702A1 (en) 2021-07-15 2024-01-18 Novo Nordisk A/S Tablet comprising a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
CN116410297A (zh) * 2021-07-19 2023-07-11 内蒙古博睿精创科技有限公司 长效glp-1多肽类似物及其制备方法和应用
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
MX2024002863A (es) 2021-09-08 2024-03-21 Shionogi & Co Medicina para la prevencion y tratamiento de enfermedades vinculadas a la actividad antiobesidad.
AU2022386166A1 (en) 2021-11-10 2024-06-20 I2O Therapeutics, Inc. Ionic liquid compositions
TWI876242B (zh) 2021-12-13 2025-03-11 丹麥商諾佛 儂迪克股份有限公司 包括環糊精的醫藥調配物
WO2023110758A1 (en) 2021-12-13 2023-06-22 Ascendis Pharma Growth Disorders A/S Effective doses of cnp conjugates
CN119137124A (zh) 2022-03-09 2024-12-13 加舒布鲁姆生物公司 杂环glp-1激动剂
WO2023179542A1 (en) 2022-03-21 2023-09-28 Gasherbrum Bio , Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
CN118973602A (zh) 2022-03-30 2024-11-15 诺和诺德股份有限公司 配制方法
CA3252113A1 (en) 2022-03-30 2023-10-05 Beijing Ql Biopharmaceutical Co., Ltd. Liquid pharmaceutical compositions of polypeptide conjugates and their methods of use
US20250250269A1 (en) 2022-04-14 2025-08-07 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN119173275A (zh) 2022-05-10 2024-12-20 诺和诺德股份有限公司 Glp-1多肽的前药及其用途
CA3249311A1 (en) 2022-05-23 2023-11-30 Ascendis Pharma Growth Disorders A/S LIQUID PHARMACEUTICAL FORMULATIONS OF CNP COMPOUNDS
WO2024010379A1 (ko) 2022-07-05 2024-01-11 주식회사 지투지바이오 세마글루타이드 또는 이의 약학적으로 허용가능한 염을 포함하는 서방성 미립구 제제 및 이의 제조방법
WO2024068848A1 (en) 2022-09-28 2024-04-04 Zealand Pharma A/S Methods for treating obesity
WO2024079043A1 (en) 2022-10-10 2024-04-18 Bachem Holding Ag Method of manufacturing a peptide with a lysine derivative
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
TW202421645A (zh) 2022-11-25 2024-06-01 丹麥商諾佛 儂迪克股份有限公司 如ｇｌｐ—１之肽治療劑的口服投與
WO2024128882A1 (ko) 2022-12-16 2024-06-20 주식회사 펩트론 Glp-1 수용체 작용제 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 미립구 및 이의 용도
CN116159027A (zh) * 2022-12-29 2023-05-26 江苏诺泰澳赛诺生物制药股份有限公司 一种司美格鲁肽冻干药物组合物及其制备方法
CN121001710A (zh) 2022-12-30 2025-11-21 阿尔吉法玛公司 提高口服多肽治疗剂的全身生物利用度的组合物和方法
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
CN120731085A (zh) * 2023-03-02 2025-09-30 甘李药业股份有限公司 一种glp-1化合物的医药用途
WO2024184354A1 (en) 2023-03-06 2024-09-12 Ascendis Pharma A/S Multi-albumin binding compounds
CN120826239A (zh) 2023-03-06 2025-10-21 阿森迪斯药物股份有限公司 包含白蛋白结合部分的药物化合物
AU2024232125A1 (en) 2023-03-06 2025-08-28 Ascendis Pharma A/S Compounds of drugs with an albumin binding moiety
CN121219011A (zh) 2023-03-20 2025-12-26 阿森迪斯药物生长障碍股份有限公司 治疗患有软骨发育不全患者胸腰椎畸形的方法
AR132255A1 (es) 2023-03-30 2025-06-11 Novo Nordisk As Compuestos de fusión y usos de estos
WO2024234320A1 (zh) * 2023-05-17 2024-11-21 南京知和医药科技有限公司 一种长效胰高血糖素样肽-1衍生物及其制备方法和用途
WO2024252366A1 (en) 2023-06-09 2024-12-12 Sun Pharmaceutical Industries Limited Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists
TW202500183A (zh) 2023-06-15 2025-01-01 丹麥商諾佛 儂迪克股份有限公司 包括環糊精的醫藥調配物
WO2025069009A1 (en) 2023-09-29 2025-04-03 Graviton Bioscience Bv Rock2 inhibitors in the treatment of obesity
WO2025077751A1 (zh) * 2023-10-09 2025-04-17 甘李药业股份有限公司 Glp-1肽组合物及其用途
WO2025078040A1 (en) 2023-10-09 2025-04-17 Bachem Holding Ag Lysine salt and method of manufacturing a lysine derivative
TW202521100A (zh) 2023-11-17 2025-06-01 美商雅沛尼美德公司（德拉瓦州公司） 使用ｇｌｐ－１受體促效劑及第二活性劑之組合治療睡眠呼吸中止之方法及組合物
WO2025114501A1 (en) 2023-11-30 2025-06-05 Novo Nordisk A/S Tri-agonists of the glp-1, gip, and amylin receptors
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025169190A2 (en) 2024-02-06 2025-08-14 Opko Biologics Ltd. Modified oxyntomodulin and methods of use thereof
EP4603080A1 (en) 2024-02-16 2025-08-20 Adocia Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4603079A1 (en) 2024-02-16 2025-08-20 Adocia Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
WO2025172606A1 (en) 2024-02-16 2025-08-21 Adocia Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
WO2025172605A1 (en) 2024-02-16 2025-08-21 Adocia Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
GB202403746D0 (en) 2024-03-15 2024-05-01 New Roger Randal Charles Formulations demonstrating an oral depot effect
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity
WO2025248124A1 (en) 2024-05-31 2025-12-04 Zealand Pharma A/S Dapiglutide for use in treating a sub-group of subjects

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990011296A1 (en) 1989-03-20 1990-10-04 The General Hospital Corporation Insulinotropic hormone
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
CA2073856C (en) 1990-01-24 2002-12-03 Douglas I. Buckley Glp-1 analogs useful for diabetes treatment
US5336782A (en) 1991-04-24 1994-08-09 Kuraray Co., Ltd. Long chain carboxylic acid imide ester
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
JP2000517308A (ja) 1996-08-30 2000-12-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―２誘導体
JP3149958B2 (ja) * 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１誘導体
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
WO1999043341A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
WO1999043705A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
EP1060192A2 (en) 1998-02-27 2000-12-20 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
AU2610899A (en) * 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
WO2000034331A2 (en) 1998-12-07 2000-06-15 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Analogues of glp-1
DK1180121T3 (da) 1999-05-17 2004-03-01 Conjuchem Inc Langtidsvirkende insulinotrope peptider
US6528486B1 (en) * 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
EP1076066A1 (en) * 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
EP1250126A2 (en) 2000-01-11 2002-10-23 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
WO2002046227A2 (en) 2000-12-07 2002-06-13 Eli Lilly And Company Glp-1 fusion proteins
FR2819810B1 (fr) 2001-01-23 2004-05-28 Pf Medicament Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
DK1412384T3 (da) 2001-06-28 2008-04-28 Novo Nordisk As Stabil formulering af modificeret GLP-1
JP2004537580A (ja) 2001-08-10 2004-12-16 エピックス メディカル， インコーポレイテッド 延長された循環半減期を有するポリペプチド結合体
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
CA2468700A1 (en) 2002-01-08 2003-07-17 Eli Lilly And Company Extended glucagon-like peptide-1 analogs
WO2004065621A1 (en) 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
EP1496924A4 (en) 2002-04-10 2007-05-30 Lilly Co Eli TREATMENT OF GASTROPARESY
US20060217300A1 (en) 2003-02-19 2006-09-28 Biomeasure, Incorporated Analogues of glp-1
EA009366B1 (ru) 2003-03-19 2007-12-28 Эли Лилли Энд Компани Связанные с полиэтиленгликолем соединения гпп-1
AU2004235872A1 (en) 2003-05-09 2004-11-18 Novo Nordisk A/S Peptides for use in treating obesity
EP1653996A2 (en) * 2003-08-08 2006-05-10 Novo Nordisk Health Care AG Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
KR101241862B1 (ko) * 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
EP1667724A2 (en) 2003-09-19 2006-06-14 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
RU2401276C2 (ru) 2003-09-19 2010-10-10 Ново Нордиск А/С Производные глюкагон-подобного пептида-1 (glp-1)
MXPA06006746A (es) 2003-12-18 2006-08-18 Novo Nordisk As Analogos de glp-1 novedosos ligados a agentes similares a albumina.
AU2004298424A1 (en) 2003-12-18 2005-06-30 Novo Nordisk A/S Novel GLP-1 compounds
EP2289560B1 (en) 2004-07-08 2015-04-22 Novo Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
US7893017B2 (en) 2004-10-07 2011-02-22 Novo Nordisk A/S Protracted GLP-1 compounds
JP5175103B2 (ja) 2004-11-12 2013-04-03 ノヴォ ノルディスク アー／エス 安定なペプチド製剤
WO2006097538A1 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Extended glp-1 compounds
TWI372629B (en) * 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
WO2006097536A2 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Dimeric peptide agonists of the glp-1 receptor

Also Published As

Publication number Publication date
DK2322546T3 (en) 2015-12-14
WO2006097537A3 (en) 2007-01-25
WO2006097537A2 (en) 2006-09-21
AU2006224536B9 (en) 2012-05-10
RU2007134156A (ru) 2009-04-27
IL184051A0 (en) 2007-10-31
AU2006224536A1 (en) 2006-09-21
CA2601784A1 (en) 2006-09-21
HUE028194T2 (en) 2016-12-28
TW200700433A (en) 2007-01-01
CA2601784C (en) 2013-12-24
RU2434019C2 (ru) 2011-11-20
US8129343B2 (en) 2012-03-06
CN101133082B (zh) 2016-01-13
JP2010116407A (ja) 2010-05-27
US8536122B2 (en) 2013-09-17
AU2006224536B2 (en) 2012-04-05
JP5209463B2 (ja) 2013-06-12
TWI372629B (en) 2012-09-21
BR122019002626A2 (OSRAM) 2019-04-02
NO337946B1 (no) 2016-07-18
NO20075342L (no) 2007-12-18
PT1863839E (pt) 2010-11-10
JP2013063984A (ja) 2013-04-11
KR20070120089A (ko) 2007-12-21
ES2557313T3 (es) 2016-01-25
US20120295847A1 (en) 2012-11-22
PT2322546E (pt) 2016-01-22
TW200942255A (en) 2009-10-16
PL1863839T3 (pl) 2011-01-31
NL300936I2 (nl) 2018-08-07
BRPI0607762B1 (pt) 2019-05-07
RU2434019C3 (ru) 2020-07-20
CN104017062A (zh) 2014-09-03
CN101133082A (zh) 2008-02-27
BRPI0607762B8 (pt) 2021-05-25
IL184051A (en) 2015-08-31
ZA200707261B (en) 2008-05-28
TWI362392B (en) 2012-04-21
JP4585037B2 (ja) 2010-11-24
EP1863839A2 (en) 2007-12-12
MX2007011220A (es) 2007-10-17
BRPI0607762A2 (pt) 2010-03-23
ATE476446T1 (de) 2010-08-15
EP2322546A1 (en) 2011-05-18
EP2322546B1 (en) 2015-09-30
ES2350051T3 (es) 2011-01-17
JP2008533105A (ja) 2008-08-21
CN104402989A (zh) 2015-03-11
DK1863839T3 (da) 2010-11-22
NO2018023I1 (OSRAM) 2018-07-05
EP1863839B1 (en) 2010-08-04
KR101205272B1 (ko) 2013-01-11
DE602006015928D1 (de) 2010-09-16
US20090156478A1 (en) 2009-06-18
HUS1800019I1 (hu) 2018-06-28

Similar Documents

Publication Publication Date Title
HUS1800019I1 (hu) Acilezett GLP-1 vegyületek
WO2006037810A3 (en) Protracted glp-1 compounds
GB0506147D0 (en) Therapeutic agents
GB0519797D0 (en) Therapeutic agents
GB0505437D0 (en) Therapeutic agents
GB0505725D0 (en) Therapeutic agents
ZA200709627B (en) Combination therapy
GB0519350D0 (en) Therapeutic agents
GB0518819D0 (en) Therapeutic agents
GB0504206D0 (en) Combination therapy
GB0518817D0 (en) Therapeutic agents
GB0509052D0 (en) Combination therapy
GB0514738D0 (en) Therapeutic agents
GB0516661D0 (en) Therapeutic agents
GB0523998D0 (en) Therapeutic agents
GB0522433D0 (en) Therapeutic agents
GB0506725D0 (en) Combination therapy
GB0526121D0 (en) Combination therapy
GB0500659D0 (en) Combination therapy
GB0502949D0 (en) Combination therapy
GB0514347D0 (en) Combination therapy
GB0500658D0 (en) Combination therapy
GB0526132D0 (en) Combination Therapy
GB0506726D0 (en) Combination therapy
GB0513778D0 (en) Combination therapy